Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-12-14 , DOI: 10.1111/apt.16739
Emma Flanagan _{1,

2} , Ralley Prentice _{1,

3,

4} , Emily K Wright _{1,

2} , Peter R Gibson _{4,

5} , Alyson L Ross ₁ , Jakob Begun ₆ , Miles P Sparrow _{4,

5} , Rimma Goldberg _{3,

4} , Ourania Rosella ₅ , Megan Burns ₃ , Katerina V Kiburg ₇ , Sally J Bell _{2,

3,

4}

Affiliation

Ustekinumab is increasingly used in pregnant women with inflammatory bowel disease (IBD). Existing safety data are reassuring, but the stability of ustekinumab levels in pregnancy, degree of transfer to the infant and time to infant clearance are unknown.

中文翻译：